Satisfaction low with mandatory transition from Humira to biosimilar in New Zealand

Patients reported low overall satisfaction with New Zealand’s mandatory nationwide transition to an adalimumab biosimilar, though most said they are still taking it and appreciated its less-painful injections, according to a study.
“While patients are frequently changed from bio-originators to biosimilars, patients’ experiences with the transitioning process are not well understood,” Chiara Gasteiger, PhD, of the University of Aukland and Stanford University, told Healio. “The adalimumab brand change was also the first large-scale mandatory community biosimilar

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart